Proactive Investors
07 Oct 2026, 12:45 UTC · 1h ago
Impact · against what's priced in
The Clarion acquisition and Taylor & Francis disposal are fundamentally neutral as the market has already factored in the funding mechanics and growth synergies. For Genflow Biosciences, the detailed SLAB study results provide positive operational momentum.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Informa is acquiring Clarion Events, funded by a £940 million equity placement and £1.3 billion in acquisition financing.
Priced inanalysis of deal by Panmure Liberum
So whatThe £940m equity placement will cause immediate dilution to existing shareholders before the Taylor & Francis disposal completes.
More positive than 93% of claims this week
Panmure Liberum forecasts Informa's FY2027 revenue will rise by 12% and EBIT by 15% following the Clarion deal.
Continue reading
5 related stories
The CEO presented detailed results from the SLAB study on SIRT6 therapy, marking the first public presentation of these findings.
Read from the article alone
No priced-in read yet
The acquisition of Clarion Events is expected to drive FY2027 revenue up by 12% and EBIT by 15%, though this is balanced by short-term leverage increasing to 2.7x and an equity placement.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Priced inanalysis of deal by Panmure Liberum
More positive than 78% of claims this week
Informa plans to dispose of Taylor & Francis, which Panmure Liberum estimates is worth approximately £2.2 billion.
Priced inanalysis of deal by Panmure Liberum
So whatAt this valuation, the asset sale fully offsets the combined £2.24bn funding requirement for Clarion.
More positive than 65% of claims this week
The acquisition is expected to push Informa's leverage to 2.7 times in FY2026 before dropping to 1.6 times by FY2028.
Priced inanalysis of deal by Panmure Liberum
So whatThe short-term leverage spike to 2.7x may temporarily restrict dividend growth or buybacks in FY2026.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Panmure Liberum reiterated a 'buy' rating and target price, citing growth and synergies from the planned acquisition of Clarion Events.
More positive than 59% of ticker scores this week
The CEO presented detailed results from a clinical study, indicating positive operational progress.
Near neutral — 91% of ticker scores this week are stronger
Mentioned only as a peer in the events industry without any specific positive or negative news.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
MarketBeat
8h ago
—
No price for GENF right now — the quote feed didn't answer.
GENF chart →—
No price for INF right now — the quote feed didn't answer.
INF chart →
